Effects of Δ9-tetrahydrocannabinol administration on human encoding and recall memory function: A pharmacological fMRI study by Bossong, Matthijs G et al.
University of Wollongong
Research Online
Faculty of Social Sciences - Papers Faculty of Social Sciences
2012
Effects of Δ9-tetrahydrocannabinol administration
on human encoding and recall memory function: A
pharmacological f MRI study
Matthijs G. Bossong
King's College London,University Medical Center Utrecht
Gerry Jager
University Medical Center Utrecht
Hendrika H. van Hell
University of Wollongong, erikavh@uow.edu.au
Lineke Zuurman
Centre for Human Drug Research, Leiden
J Martijn Jansma
University Medical Center Utrecht
See next page for additional authors
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Bossong, M. G., Jager, G., van Hell, H. H., Zuurman, L., Jansma, J. Martijn., Mehta, M. A., van Gerven, J. M. A., Kahn, R. S. & Ramsey,
N. F. (2012). Effects of Δ9-tetrahydrocannabinol administration on human encoding and recall memory function: A pharmacological
fMRI study. Journal of Cognitive Neuroscience, 24 (3), 588-599.
Effects of Δ9-tetrahydrocannabinol administration on human encoding
and recall memory function: A pharmacological f MRI study
Abstract
Deficits in memory function are an incapacitating aspect of various psychiatric and neurological disorders.
Animal studies have recently provided strong evidence for involvement of the endocannabinoid (eCB) system
in memory function. Neuropsychological studies in humans have shown less convincing evidence but suggest
that administration of cannabinoid substances affects encoding rather than recall of information. In this study,
we examined the effects of perturbation of the eCB system on memory function during both encoding and
recall. We performed a pharmacological MRI study with a placebo-controlled, crossover design, investigating
the effects of Δ9-tetrahydrocannabinol (THC) inhalation on associative memory-related brain function in 13
healthy volunteers. Performance and brain activation during associative memory were assessed using a
pictorial memory task, consisting of separate encoding and recall conditions. Administration of THC caused
reductions in activity during encoding in the right insula, the right inferior frontal gyrus, and the left middle
occipital gyrus and a network-wide increase in activity during recall, which was most prominent in bilateral
cuneus and precuneus. THC administration did not affect task performance, but while during placebo recall
activity significantly explained variance in performance, this effect disappeared after THC. These findings
suggest eCB involvement in encoding of pictorial information. Increased precuneus activity could reflect
impaired recall function, but the absence of THC effects on task performance suggests a compensatory
mechanism. These results further emphasize the eCB system as a potential novel target for treatment of
memory disorders and a promising target for development of new therapies to reduce memory deficits in
humans.
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Abstract
■ Deficits in memory function are an incapacitating aspect of
various psychiatric and neurological disorders. Animal studies
have recently provided strong evidence for involvement of the
endocannabinoid (eCB) system in memory function. Neuro-
psychological studies in humans have shown less convincing evi-
dence but suggest that administration of cannabinoid substances
affects encoding rather than recall of information. In this study, we
examined the effects of perturbation of the eCB system on mem-
ory function during both encoding and recall. We performed a
pharmacological MRI study with a placebo-controlled, crossover
design, investigating the effects of Δ9-tetrahydrocannabinol
(THC) inhalation on associative memory-related brain function
in 13 healthy volunteers. Performance and brain activation during
associative memory were assessed using a pictorial memory task,
consisting of separate encoding and recall conditions. Adminis-
tration of THC caused reductions in activity during encoding
in the right insula, the right inferior frontal gyrus, and the left
middle occipital gyrus and a network-wide increase in activity
during recall, which was most prominent in bilateral cuneus
and precuneus. THC administration did not affect task perfor-
mance, but while during placebo recall activity significantly
explained variance in performance, this effect disappeared after
THC. These findings suggest eCB involvement in encoding of
pictorial information. Increased precuneus activity could reflect
impaired recall function, but the absence of THC effects on
task performance suggests a compensatory mechanism. These
results further emphasize the eCB system as a potential novel
target for treatment of memory disorders and a promising
target for development of new therapies to reduce memory
deficits in humans. ■
INTRODUCTION
Learning and memory are critical in our daily lives. Deficits
in memory function are associated with various psychiatric
and neurological disorders, such as Alzheimer disease,
schizophrenia, and mood disorders, and can be severely
incapacitating.
Recently, animal studies have provided strong evidence
for the involvement of the endocannabinoid (eCB) system
in memory (Wise, Thorpe, & Lichtman, 2009; Wegener,
Kuhnert, Thuns, Roese, & Koch, 2008; Yim, Hong,
Ejaredar, McKenna, & McDonald, 2008; Hampson &
Deadwyler, 2000; Mallet & Beninger, 1998; Lichtman &
Martin, 1996; Lichtman, Dimen, & Martin, 1995). The eCB
system, consisting of cannabinoid receptors and accom-
panying endogenous ligands, is a retrograde messenger
system that regulates both excitatory and inhibitory neuro-
transmission (Piomelli, 2003; Wilson & Nicoll, 2002). As
such, the eCB system may act to “fine tune” the control
of important brain functions, including learning and mem-
ory (Ranganathan & DʼSouza, 2006).
Modulation of the eCB system by systemic administration
of exogenous cannabinoids, such as Δ9-tetrahydrocannabinol
(THC), the main psychoactive component in cannabis and
partial agonist of the CB1 receptor, impairs performance
on various learning and memory paradigms in animals
(Wise et al., 2009; Wegener et al., 2008; Yim et al., 2008;
Hampson & Deadwyler, 2000; Mallet & Beninger, 1998;
Lichtman & Martin, 1996; Lichtman et al., 1995). This sug-
gests that the eCB systemmay be an important target for the
development of novel therapies for memory dysfunction in
psychiatric disorders. However, animal findings may not
directly translate to humans, and there is a need to study
the specific role of the eCB system in humans.
In humans, cannabinoids produce a diverse range of
acute effects (Hall & Solowij, 1998), with increases in heart
rate and subjective effects such as “feeling high” as the
strongest andmost consistently reportedmeasures (Zuurman,
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Ippel, Moin, & van Gerven, 2009). Despite the consistent
findings of memory impairments in animals after cannabi-
noid administration and the robust cannabinoid-induced
human subjective and physiological effects, the evidence
for impact of cannabinoid intoxication on learning and
memory performance is less convincing. A large number
of neuropsychological studies have reported no acute
effects of cannabinoid administration on learning and
memory paradigms (Hart et al., 2002, 2010; Zuurman et al.,
2009; McDonald, Schleifer, Richards, & de Wit, 2003;
Hart, van Gorp, Haney, Foltin, & Fischman, 2001; Chait &
Perry, 1994; Block &Wittenborn, 1984; Darley, Tinklenberg,
Roth, Vernon, & Kopell, 1977). Recall of items acquired be-
fore cannabis use is also generally not affected (Dornbush,
1974; Darley, Tinklenberg, Roth, Hollister, & Atkinson,
1973; Abel, 1971). Effects of cannabinoids on memory per-
formance have, however, been reported in the free recall
of information that is previously learned under the influ-
ence of cannabinoids (DʼSouza et al., 2004; Curran,
Brignell, Fletcher, Middleton, & Henry, 2002; Miller &
Cornett, 1978). This suggests that cannabinoids influence
encoding but not recall of information. Notwithstanding
reported effects on memory in humans, the effect size is
typically surprisingly small.
Assuming that the eCB system does play an important
role in memory in both humans and animals, neuropsy-
chology results may be affected by the ability of the human
brain to reduce the effects of perturbations of the eCB
system on behavior by functional compensation. A more
effective method to measure the role of eCB in memory
function in humans can be provided by direct visualization
of brain activity during performance of a memory task in a
pharmacological fMRI study.
In this study, we applied this approach and measured
the effect of THC administration on encoding and recall
brain function in an fMRI study. On the basis of neuro-
psychological findings, we tested the hypothesis that THC
administration affects encoding, resulting in reduced
encoding-related brain activity in a memory network in-
cluding (para)hippocampal and prefrontal areas ( Jager et al.,
2007; Henke, Buck, Weber, & Wieser, 1997). In addition, in
line with neuropsychological findings, we did not expect
direct effects of THC on recall processes, although com-
pensatory mechanisms for the affected encoding function
may lead to increases in activity during recall. These hypoth-
eses were tested in an fMRI study with a double-blind, ran-
domized, placebo-controlled, crossover design, using a
pictorial associative memory task, containing separate
encoding and recall conditions (Jager et al., 2007; Henke
et al., 1997).
METHODS
This study is part of the Pharmacological Imaging of the
Cannabinoid System study, of which design and objectives
are provided in a methods paper (van Hell, Bossong, Jager,
Kahn, & Ramsey, 2011).
Subjects
Fourteen healthy male right-handed subjects were recruited
through advertisements on the Internet and in local news-
papers. All subjects used cannabis on an incidental basis,
defined as having used cannabis at least four times but at
most once a week in the year before inclusion in the study.
All subjects were in good physical health as assessed by
medical history, physical examination, electrocardiogram
(ECG), and routine laboratory tests. Subjects were asked
to refrain from cannabis for at least 2 weeks before the first
study day until study completion. A maximum use of five
cigarettes per day was allowed. Illicit drug use other than
cannabis was restricted to a maximum of five times lifetime
and not within 6 months before inclusion. Urine screening
for cannabis, cocaine, amphetamine, methamphetamine,
3,4-methylenedioxymethamphetamine, morphine, metha-
done, tricyclic antidepressants, barbiturates, and benzodi-
azepines was performed at screening and on both study
days. Subjects with a positive drug test were excluded from
the study. Subjects were also asked to abstain from alcohol
for 48 hr before each study day. Smoking was not allowed
from the moment of arrival until the end of a study day.
Alcohol and nicotine use was assessed by self-report. Sub-
jects were asked to fast for at least 4 hr before arrival. On
the beginning of each test day, they were served a standard
meal. For further details on inclusion and exclusion criteria,
we refer to van Hell et al. (2011). All volunteers gave written
informed consent before entry into the study and were
compensated for their participation. The study was approved
by the University Medical Center Utrecht Independent
Ethics Committee.
Results are reported on 13 of the 14 included subjects.
One subject did not complete the second scanning session
because of anxiety. See Table 1 for subject characteristics.
Design and Procedure
In a double-blind, randomized, placebo-controlled, cross-
over pharmacological MRI study, subjects underwent two
scanning sessions after either administration of placebo
or THC. Study days were scheduled 2 weeks apart to allow
for complete clearance of drugs. Two weeks before the
first study day, participants were familiarized with the
scanner environment using a mock scanner. Verbal intel-
ligence was estimated with the Dutch Adult Reading Test,
the Dutch version of the National Adult Reading Test
(Schmand, Bakker, Saan, & Louman, 1991).
At the beginning of each study day, a catheter was
placed percutaneously in the left arm for the withdrawal
of blood samples. Subsequently, subjects performed
three cognitive paradigms, during which fMRI scans were
obtained. One of these paradigms was the associative
memory task. Paradigm sequence was randomized be-
tween subjects but remained unchanged within subjects
across sessions. Results of the other two paradigms are re-
ported elsewhere.
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On study days, subjects received subsequent doses of
THC or placebo with 30-min intervals. Drugs were
administered before each fMRI task using a Volcano
vaporizer (Storz-Bickel GmbH, Tuttlingen, Germany) ac-
cording to a method described earlier (Bossong et al.,
2009; Zuurman et al., 2008; Hazekamp, Ruhaak, Zuurman,
van Gerven, & Verpoorte, 2006). The first THC dose was
6 mg, followed by three doses of 1 mg each to maintain
stable levels of CNS effects throughout the scanning
procedure. Doses were based on pharmacokinetic/
pharmacodynamic modeling of CNS effects induced by
THC (Strougo et al., 2008; see van Hell et al., 2011, for
detailed study procedures).
Drug Levels and Behavioral Measurements
Venous blood samples were collected to determine plasma
concentrations of THC and its twomost important metabo-
lites, 11-OH-THC and 11-nor-9-carboxy-THC. Blood sam-
ples were processed according to Zuurman et al. (2008).
Subjective and psychedelic effects were determined with
two sets of visual analogue scales (VAS; Bowdle et al.,
1998; Bond & Lader, 1974). Both rating scales were per-
formed consecutively at baseline and before and after per-
formance of the associative memory task. VAS were
analyzed as described previously (Zuurman et al., 2008).
Correlations between THC peak concentration and behav-
ioral changes (THC vs. placebo) were determined using
Pearsonʼs correlation coefficient. Heart rate and respiration
were monitored continuously during scanning, as de-
scribed by van Buuren et al. (2009). Mean heart rate was
calculated by dividing the total number of heart beat trigger
signals by the duration of the associative memory task.
Data were corrected for baseline values and analyzed with
paired t tests.
Task Paradigm
Associative memory was assessed with a pictorial memory
task (PMT) involving three different task conditions (Figure 1;
Jager et al., 2007; Henke et al., 1997). First, an encoding
condition (EN) was conducted in which subjects were pre-
sented with two pictures, one of a person and one of a
house. Subjects were asked to decide whether the person
might either be an inhabitant or a visitor of the house and
to memorize the combination of pictures. There was no
correct or incorrect answer. The purpose of the instruction
Figure 1. Schematic outline




in which subjects were
presented with two pictures:
one of a person and one of a
house. In the second condition,
identical pictures had to be
classified as a house or a person
(“SIMPLE CLASSIFICATION”).
This condition was the control
condition. The third condition
was a recall task (“RECALL”),
which required subjects to
recognize specific combinations
of pictures previously presented
during ENCODING. Half of the
stimuli were new combinations,
and half were combinations
previously presented.
Table 1. Subject Characteristics (n = 13)
Characteristic Mean± SD Range
Age (years) 21.6 ± 2.1 18–27
IQ 104.8 ± 5.6 94–111
Height (cm) 185.9 ± 5.3 176–196
Weight (kg) 78.7 ± 9.1 64–96
BMI (kg/m2) 22.7 ± 2.3 18.6–27.8
Cannabis use (occasions/year) 17.0 ± 12.4 5–52
Tobacco smoking (cigarettes/week) 2.7 ± 7.7 0–28
Alcohol consumption (units/week) 16.7 ± 8.7 2–30
Coffee consumption (units/week) 11.2 ± 9.9 0–28
Illicit drug use (occasions lifetime) 1.3 ± 1.6 0–4
Use of cannabis, tobacco, alcohol, and coffee was given for the year
before inclusion in the study. Subjects refrained from cannabis for at
least 2 weeks before the first study day until study completion and from
alcohol for 48 hr before each study day. Caffeine intake and smoking
were not allowed from the moment of arrival until the end of a study day.
Illicit drug use other than cannabis was at least more than 6 months
before the first study day. All subjects showed negative urine screening
at both study days.
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was to engage subjects in a semantic evaluation of the two
pictures which was expected to lead to a deep level of
encoding of the paired pictures, irrespective of the deci-
sion. In the second condition, single item pictures had to
be classified (denoted as SC). Two identical pictures were
shown and subjects had to indicate whether a house or a
person was presented. This condition was chosen as a con-
trol task. SC requires identical amount of perceptual pro-
cessing and motor response as the two experimental
conditions, but without a memory component. The third
condition was a recall task (RE), which required subjects
to recognize specific combinations of pictures previously
presented during EN. Half of the stimuli were new combi-
nations, and half were combinations previously presented
during EN. For all conditions, subjects were instructed to
press one of two buttons according to the instruction in
the respective task condition, with emphasis on accuracy
without stressing speed of response.
Each task condition was presented in an epoch con-
sisting an instruction slide of 4000 msec followed by six
stimuli. Each stimulus contained two pictures on a white
background and was presented for 4000 msec, followed
by an 850-msec fixation cross. Rest periods of half the
epoch duration were also included. Altogether, a fixed
order sequence of all task conditions was repeated four
times, resulting in total task duration of 9 min. The PMT
task contained different stimuli on both study days. Per-
formance accuracy was assessed for SC and RE and was
calculated as the mean percentage of correctly identified
stimuli.
Image Acquisition
Image acquisition was performed on a Philips Achieva
3.0-T scanner (PhilipsMedical Systems, Best, the Netherlands).
Functional images were obtained using a 3-D PRESTO-
SENSE pulse sequence (Neggers, Hermans, & Ramsey,
2008) with shimmed background and the following param-
eters: repetition time= 22.5 msec, echo time= 33.2 msec,
flip angle = 10°, field of view = 224 × 256 × 160, matrix =
56 × 64 × 40, voxel size = 4 mm isotropic, scan time =
0.6075 sec, 40 slices (sagittal orientation). A total of 900
functional images were acquired. Immediately after the
PMT task, one volume with a flip angle of 27° was acquired
for image coregistration. A T1-weighted structural image
was obtained for anatomical registration with the following
parameters: repetition time = 9.5 msec, echo time =
4.7 msec, flip angle = 8°, field of view = 220.8 × 240 ×
159.6, matrix = 368 × 400 × 266, voxel size = 0.6 mm
isotropic, 266 slices (sagittal orientation).
fMRI Analysis
After reconstruction, imaging data were preprocessed
and analyzed using SPM5 (Wellcome Trust Centre for
Neuroimaging, London, United Kingdom). Preprocessing
of data included realignment of functional images and
coregistration with the anatomical scan using the volume
with a flip angle of 27°. Subsequently, functional scans
were spatially normalized into MNI space (Collins, Neelin,
Peters, & Evans, 1994) and smoothed (FWHM = 8 mm).
For each individual subject, regression coefficients for
each voxel (b values) were obtained from a general linear
model regression analysis using a factor matrix that con-
tained factors modeling the EN, SC, and RE conditions
(four blocks each) as well as the instructions that were
presented during the task. To correct for drifts in the sig-
nal, a high-pass filter with a cutoff frequency of 0.005 Hz
was applied to the data.
We chose to perform ROI analyses including areas that
were involved in the task, as this analysis provides a good
balance between power and information and allows for
calculation and presentation of effect sizes (Kriegeskorte,
Simmons, Bellgowan, & Baker, 2009; Poldrack, 2007).
Group activation maps were created for the contrasts
EN–SC and RE–SC for both the placebo and THC condi-
tion. All four maps were thresholded (t = 4.5, p < .05,
corrected for multiple comparisons) and placebo and
THC maps were pooled, resulting in two group activation
maps (EN–SC and RE–SC). For both the EN–SC and RE–SC
contrasts, clusters of at least 10 neighboring voxels were
defined as ROIs, thus resulting in two sets of ROIs. Con-
structing the ROIs based on the highest values in either
the THC or the placebo session prevents bias toward either
the placebo or THC session (Mehta & OʼDaly, 2011;
Kriegeskorte et al., 2009). Mean signal change for each
ROI, each subject, and each session (placebo and THC)
was based on regression coefficients (b values) averaged
over voxels in each ROI, extracted using Marsbar (Brett,
Anton, Valabregue, & Poline, 2002).
To measure THC effects on encoding, a repeated
measures MANOVA was performed on ROIs based on the
EN–SC contrast with drug (2 levels: THC and placebo),
condition (2 levels: EN and SC), and ROI (10 levels) as
within-subject factors. Post hoc paired t test analyses were
performed in comparison with SC to further investigate
effects in individual ROIs. To measure effects of THC on
recall activity, a repeated measures MANOVA was per-
formed on ROIs based on the RE–SC contrast with Drug
(two levels), Condition (two levels: RE and SC), and ROI
(seven levels) as within-subject factors. Follow-up paired
t test analyses were again performed for every ROI.
To assess relationships between brain activity and per-
formance and to determine whether activity patterns
within involved networks predicted performance, regres-
sion analyses were conducted with ROIs as independent
variables and accuracy as dependent variable. This was
done for each set of ROIs (encoding and recall) and for
each session (placebo, THC). If the overall general linear
model was significant, individual follow-up correlation
analyses were performed between performance and ROIs.
Post hoc paired t tests were not corrected for multiple
comparisons if the main MANOVA effect was significant,
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as they were considered as a further exploration of an
already significant effect. All hypothesis tests were per-
formed using SPSS 17.
RESULTS
Drug Levels and Behavioral Measurements
THC plasma concentration reached a maximum of 58.1 ±
31.3 ng/ml 5 min after inhalation of 6 mg THC and
decreased rapidly thereafter. Subsequent doses of 1 mg
THC induced peaks in THC plasma concentration of
13.7 ± 7.7, 13.0 ± 3.8, and 13.8 ± 6.0 ng/ml 5 min after
each respective dose.
Analysis of subjective and psychedelic effects before
and after performance of PMT revealed a significant
THC-induced increase in VAS score of “feeling high”
(F(1, 12) = 9.98, p= .008) and a decrease on “alertness”
(F(1, 12) = 13.95, p = .003) compared with placebo. In
addition, THC caused a trend toward both increased in-
ternal perception (reflecting inner feelings that do not
correspond with reality) and external perception (re-
flecting misperception of external stimuli or changes in
the awareness of the environment; F(1, 12) = 3.79, p =
.075 and F(1, 12) = 3.46, p = .087, respectively). Subjec-
tive and psychedelic effects are summarized in Table 2.
Peak THC concentration was positively correlated with
alterations (THC vs. placebo) in “feeling high” (r = .620;
p = .031) and negatively with changes in “alertness” (r =
−.746, p = .005).
Heart rate increased significantly after THC compared
with placebo (8.5 ± 10.2 and 2.1 ± 4.9 bpm increase com-
pared with baseline, respectively; p = .046). For a more
detailed description of drug levels and behavioral mea-
surements following THC, see van Hell et al. (2011).
Task Performance
Performance accuracy on the PMT task did not differ
between THC and placebo sessions for both SC (99.4 ±
0.4% for both sessions; p= 1.000) and RE (91.4 ± 3.3 and
89.4 ± 2.5%, respectively; p = .430; Figure 2).
Selection of ROIs
The EN–SC contrast yielded a network of ten brain regions,
comprising bilateral fusiform gyrus/parahippocampal
gyrus, inferior frontal gyrus, insula and middle occipital
gyrus, right putamen, and left SMA (Table 3).
The RE–SC contrast showed a network of seven regions,
comprising bilateral fusiform/parahippocampal gyrus,
cuneus/precuneus, middle occipital gyrus, and left supe-
rior parietal gyrus (Table 4).
Effects of THC on Encoding Activity
For the 10 encoding ROIs, a significant interaction effect
was found between condition, drug, and ROI (F(9, 108) =
2.20, p= .028). This indicates that THC induced a change
in the pattern of activity during encoding. There was a
trend toward a significant effect of drug (F(1, 12) =
4.15, p = .064) but no significant difference in the effect
of THC on conditions (Drug × Condition, F(1, 12) = 2.47;
p = .142). To elucidate which ROIs were involved in the
Table 2. Subjective and Psychedelic Effects of THC (n = 13)
Assessment Drug Effect Placebo Score (Mean± SD) THC Score (Mean± SD)
VAS feeling high F(1, 12) = 9.98, p = .008a 0.38 ± 1.39 17.31 ± 19.16
VAS internal perception F(1, 12) = 3.79, p = .075 −0.35 ± 1.41 1.69 ± 3.78
VAS external perception F(1, 12) = 3.46, p = .087 0.35 ± 0.72 6.76 ± 12.43
VAS alertness F(1, 12) = 13.95, p = .003a −2.09 ± 7.00 −13.57 ± 9.38
VAS contentedness F(1, 12) = 1.09, p = .318 −2.77 ± 3.64 −4.85 ± 6.69
VAS calmness F(1, 12) = 2.44, p = .144 3.56 ± 8.97 −2.21 ± 11.12
Statistical analysis was performed with baseline-corrected values using repeated measures ANOVA with Drug and Time as factors.
aSignificant difference between placebo and THC.
Figure 2. Performance accuracy on the PMT task during simple
classification (left) and recall (right) in placebo session (white bars) and
THC session (black bars). There was no significant difference in
performance between sessions (n = 13; mean ± SEM ).
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significant interaction, post hoc analyses (not corrected
for multiple comparisons) were performed on each ROI.
These demonstrated significantly reduced brain activity
after THC administration (relative to placebo) in the right
insula (from 0.53 ± 0.07 to 0.33 ± 0.06, p = .019), right
inferior frontal gyrus (from 0.54 ± 0.09 to 0.22 ± 0.17, p=
.031), and left middle occipital gyrus (from 0.54 ± 0.06 to
0.39 ± 0.07, p = .033). The mean b values are shown in
Figure 3.
Effects of THC on Recall Activity
Repeated measures analysis showed no significant effect of
Drug (F(1, 12) = 1.14, p = .306) in the seven recall ROIs,
but THC affected the RE and SC conditions significantly
differently (Drug × Condition, F(1, 12) = 5.92; p = .032). A
significant interaction effect between Condition, Drug, and
ROI (F(6, 72) = 3.02; p= .011) indicated that these Drug ×
Condition effects differed between ROIs. Post hoc analy-
sis (not corrected for multiple comparisons) showed a sig-
nificant THC-induced increase in brain activity relative to
placebo in the left (from 0.37 ± 0.11 to 0.76 ± 0.09, p =
.014) and right precuneus (from 0.33± 0.09 to 0.78 ± 0.10,
p = .004; for mean b values, see Figure 4).
Brain Activity versus Performance
Overall THC administration did not affect performance.
To assess whether activity patterns within involved net-
works predicted performance, regression analyses were
Table 3. Significantly Activated Brain Regions during Encoding (n = 13)
Encoding—Single Classification
Activated Brain Regions Brodmannʼs Area Number of Voxels x y z Maximum t Value
Fusiform/parahippocampal gyrus L 37 291 −28 −52 −12 13.10
Fusiform/parahippocampal gyrus R 37 330 36 −60 −20 15.44
Inferior frontal gyrus L 44 13 −56 24 28 5.30
Inferior frontal gyrus R 48 19 40 16 28 5.97
Insula L 47 28 −32 28 −4 6.25
Insula R 47 22 40 24 −4 7.45
Middle occipital gyrus L 19 271 −28 −80 16 11.96
Middle occipital gyrus R 39 244 40 −80 24 9.82
Putamen R 48 17 20 8 16 5.57
SMA L 6 37 4 16 52 6.25
Group activation maps for placebo and THC were thresholded at t = 4.5, p < .05, corrected for multiple comparisons, cluster size ≥ 10 voxels. x, y,
and z are MNI coordinates and represent the highest t value in a cluster. Brodmannʼs areas are obtained from the location in the AAL atlas indicated
by the MNI coordinates. L = left; R = right.
Table 4. Significantly Activated Brain Regions during Recall (n = 13)
Recall—Single Classification
Activated Brain Regions Brodmannʼs area Number of Voxels x y z Maximum t Value
Cuneus/precuneus L 19 182 −12 −72 40 11.21
Cuneus/precuneus R 23 167 12 −68 24 8.27
Fusiform/parahippocampal gyrus L 37 180 −32 −44 −12 10.83
Fusiform/parahippocampal gyrus R 37 210 40 −56 −20 8.54
Middle occipital gyrus L 19 14 −28 −84 24 6.12
Middle occipital gyrus R 19 94 32 −72 20 7.90
Superior parietal gyrus L 19 179 −12 −72 40 11.21
Group activation maps for placebo and THC were thresholded at t = 4.5, p < .05, corrected for multiple comparisons, cluster size ≥ 10 voxels. x, y,
and z are MNI coordinates and represent the highest t value in a cluster. Brodmannʼs areas are obtained from the location in the AAL atlas indicated
by the MNI coordinates. L = left; R = right.
Bossong et al. 593
Figure 3. Brain activity during
encoding (EN–SC). (A) Group
activation maps after placebo
(top) and THC (bottom)
administration (n = 13; t > 4.5,
p < .05, corrected for multiple
comparisons, clusters ≥ 10
voxels). L = left; R = right.
(B) Effect of THC administration
on brain activity in the right
insula, the right inferior frontal
gyrus, and the left middle
occipital gyrus (mean ± SEM ).
*p < .05. a.u. = arbitrary units;
IFR = inferior frontal gyrus;
MOG = middle occipital gyrus.
Figure 4. Brain activity during
recall (RE–SC). (A) Group
activation maps after placebo
(top) and THC (bottom)
administration (n = 13;
t > 4.5, p < .05, corrected
for multiple comparisons,
cluster size ≥ 10 voxels).
L = left, R = right. (B) Effect
of THC administration on
brain activity in the bilateral
cuneus/precuneus (mean ± SEM).
*p < .05. a.u. = arbitrary units.
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conducted with ROIs as independent variables and accu-
racy as dependent variable for each set of ROIs (encoding
and recall) and for each session (placebo, THC). This re-
vealed that during the placebo session a significant part
of the variance in performance was explained by recall ac-
tivity (F= 17.37, p= .003), but not during the THC session
(F = 0.65, p = .71). Encoding activity patterns contained
no predictive value for performance during placebo (F =
0.54, p = .79) or THC (F = 0.90, p = .63). A closer look
at individual recall ROIs for the placebo session indicated
that three of seven were negatively correlated with per-
formance: left fusiform/parahippocampal gyrus (r =
−.83, p < .001) and left and right middle occipital gyrus
(r = −.63, p = .02 and r = −.82, p = .001, respectively;
Figure 5). This shows that, under normal circumstances,
good performance is associated with low activity in these
regions during recall whereas this association disappears
after THC.
DISCUSSION
This study tested the hypothesis that a cannabinoid chal-
lenge affects associative memory processes in humans.
Activity in the network of regions involved in encoding
of paired pictorial stimuli was significantly affected by
THC administration, with reduced levels of activity in
the right insula, right inferior frontal gyrus, and left middle
occipital gyrus. During recall, THC administration was
associated with a network-wide increase in activity, which
was strongest in a bilateral region comprising cuneus and
precuneus. Recall performance was not affected by THC
administration. However, during the placebo session re-
call activity significantly explained variance in perfor-
mance, with a strong inverse correlation in fusiform/
parahippocampal and middle occipital gyrus, indicating
that good performance was associated with low activity.
This association disappeared after THC. Our interpreta-
tion is that under normal circumstances some subjects
were able to use a very efficient recognition strategy for
recall if information was sufficiently deep encoded. After
THC, these subjects were mostly affected, as they could
not apply this efficient recall strategy anymore. Hence,
the inverse correlation between performance and recall
activity disappeared after THC, although average perfor-
mance itself was not reduced.
Although the design of the study does not provide con-
clusive evidence concerning the stage of memory process-
ing that is most affected by THC, several arguments can be
made for encoding as being more directly affected by THC,
whereas the changes during recall are more likely to reflect
a form of compensation for the affected encoding. First,
THC induced opposite activity changes in encoding and re-
call. The interpretation that THC reduced encoding depth,
indicated by less activity, while subjects could compensate
during recall, at the expense of more activity, fits these dif-
ferential effects. Second, behavioral studies in humans
have indicated impairments in the free recall of informa-
tion that is previously learned under the influence of can-
nabinoids (DʼSouza et al., 2004; Curran et al., 2002; Miller &
Cornett, 1978), but recall of items acquired before cannabis
use is generally not affected (Dornbush, 1974; Darley et al.,
1973; Abel, 1971), which indicates that cannabinoids influ-
ence encoding but not recall of information. Third, as task
performance did not reach a ceiling during placebo, it was
optimally sensitive to detect any changes in performance.
Still, no performance effects were found, which suggests
that subjects were able to compensate for the effects of
THC. An alternative explanation could be that THC did also
directly affect the recall process, for instance, by disturbing
the retrieval process of previously encoded information.
However, this interpretation would be in contrast with
the mentioned previous findings that have indicated that
THC does not affect recall of material encoded before
drug intake.
In the absence of effects of THC on associative memory
performance, it could be argued that the reported effects
of THC may not be related to associative memory but are
rather caused by nonspecific effects of THC intoxication.
There are, however, several reasons to argue that the effects
are indeed related to associative memory.
Figure 5. Correlation between
recall brain activity and
performance accuracy during
placebo (A) and THC (B). The
left fusiform/parahippocampal
and bilateral middle occipital
gyrus showed a significant
inverse correlation with
performance in the placebo
session ( p < .05), whereas
there was no significant
correlation with performance
in the THC session nor in any
of the other ROIs. a.u. =
arbitrary units.
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First, as mentioned earlier, the opposite effect of THC
on encoding and recall activity suggests differential effects
of THC that are specific for each process and not task
independent. Second, the reduced correlation between
performance and recall activity after THC indicates a di-
rect effect of THC on the association between brain activ-
ity and task performance. Third, the reported effects of
THC on brain activity reflect differences between the
control and experimental task. These differences lie pre-
dominantly in the addition of an associative memory
component in the experimental task. Thus, the effects
of THC on brain activity are most likely associated with
processes that directly or indirectly affect associative
memory. Intoxicating, task-independent effects of THC
can be expected to be present in both the control and
experimental task.
Several fMRI studies have suggested important roles for
some of the brain regions implicated in memory encoding
in the current study (Dobbins, Foley, Schacter, & Wagner,
2002; Kelley et al., 1998; Wagner et al., 1998). The insula
has been implicated in the process of selecting relevant
item information, whereas the inferior frontal gyrus has
been implicated in the organization of multiple pieces
of information, possibly by building associations among
items (Blumenfeld & Ranganath, 2007; Staresina & Davachi,
2006; Summerfield et al., 2006; Simons & Spiers, 2003).
The middle occipital gyrus may not only be involved in
the visual processing of to-be-remembered stimuli (Ishai,
Ungerleider, Martin, & Haxby, 2000), but also in mainte-
nance and imagery of visual information (Johnson, Mitchell,
Raye, DʼEsposito, & Johnson, 2007). As all these functions
include attentional processes and the right insula and infe-
rior frontal gyrus are part of the ventral attention network
(Corbetta, Patel, & Shulman, 2008; Corbetta & Shulman,
2002), the decrease in activity in these brain areas after
THC administration may be related to disturbed attentional
processes, which is in line with the reported THC-induced
reduction in alertness.
A possible alternative interpretation for the reduced
encoding activity after THC would be that encoding was
performed more efficiently under the influence of THC.
However, both animal and human behavioral studies
argue against this, as previous studies have not indicated
increased efficiency of encoding after THC, only impair-
ments (e.g., Wise et al., 2009; Wegener et al., 2008; Yim
et al., 2008; DʼSouza et al., 2004; Curran et al., 2002;
Hampson & Deadwyler, 2000; Lichtman et al., 1995; Miller
& Cornett, 1978).
A potential mechanism underlying the THC-induced
decreases in brain activity may be found in the regulatory
role of the eCB system in neurotransmitter release. As
shown in electrophysiological animal studies, activation of
cannabinoid receptors reduces both GABA and glutamate
release from presynaptic terminals (Heifets & Castillo,
2009; Wilson & Nicoll, 2002). This eCB-mediated inhibition
of synaptic transmission is critically involved in learning and
memory processes (Heifets & Castillo, 2009) and has been
demonstrated in the PFC (Lafourcade et al., 2007), among
other brain regions.
In our study, we found an increase in activity in bilateral
precuneus after THC during recall. Previous imaging stud-
ies have suggested a pivotal role for the bilateral cuneus
and precuneus in recall memory (Wiesmann & Ishai, 2008;
Gardini, Cornoldi, De Beni, & Venneri, 2006; Lundstrom,
Ingvar, & Petersson, 2005; Gilboa, Winocur, Grady, Hevenor,
& Moscovitch, 2004; Lundstrom et al., 2003; Burgess,
Maguire, Spiers, & OʼKeefe, 2001; Henson, Rugg, Shallice,
Josephs, & Dolan, 1999; Krause et al., 1999; Fletcher et al.,
1995). It is suggested that the (pre)cuneus is particularly
involved in recall of context-rich memories, such as mem-
ories entailing specific contextual associations (Gardini
et al., 2006; Lundstrom et al., 2003, 2005; Gilboa et al.,
2004; Henson et al., 1999). Increased involvement of the
precuneus has been demonstrated when subjects claimed
to recognize items based on conscious recollection of
contextual details rather than on feelings of familiarity
(Wiesmann & Ishai, 2008; Wheeler & Buckner, 2004;
Henson et al., 1999). More specifically, it may signal
whether context information should be used to recognize
an item correctly (Dorfel, Werner, Schaefer, von Kummer,
& Karl, 2009). The enhanced precuneus activity found in
the current study after THC administration thus could be
related to a change in retrieval strategy, with increased
utilization of contextual associations to accurately recall
information. One mechanism would be that after THC ad-
ministration recall relies more on processing of individual
features of to-be-remembered items, such as the color of a
personʼs shirt, than on the recognition of the complete
composition of the picture, which can be expected to be
more efficient. Importantly, increases in precuneus activity
during recall memory have also been associated with
compensatory mechanisms in individuals with and at risk
for mild cognitive impairment or Alzheimerʼs disease
(Schwindt & Black, 2009; Seidenberg et al., 2009; Woodard
et al., 2009).
To date, only one other fMRI study has been published
that investigated the acute effects of THC administration
on learning and memory (Bhattacharyya et al., 2009). A
normal linear decrease in activity in the parahippocampal
gyrus present over repeated encoding blocks was no
longer evident after oral THC administration. As in the
current study, task performance was unaffected. Because
Bhattacharyya and colleagues presented the same stimuli
during four blocks of encoding, thereby investigating the
effect of THC on learning activity, only the imaging results
for the first presentation of stimuli are comparable to our
study. These findings are in line with our results in that a
THC-induced reduction in encoding activity was found.
However, differences in recall activity in the first session
were not reported (Bhattacharyya et al., 2009).
This study has several limitations. First, the sample size
was relatively small. We therefore cannot exclude the pos-
sibility that subtle effects of THC on brain activity have
been missed. Second, inclusion of incidental cannabis
596 Journal of Cognitive Neuroscience Volume 24, Number 3
users, as opposed to nonusers, may have hampered inter-
pretation of the results, as previous cannabis use may
have affected the eCB system. The choice for incidental
cannabis users was based on ethical grounds (van Hell
et al., 2011). Third, absence of significant differences
between placebo and THC in performance accuracy may
suggest that the memory task used in this study was not
an appropriate task to assess memory function. However,
we have previously shown that performance on this task
correlates inversely with the amount of cannabis used
in the year before testing, in heavy cannabis users ( Jager
et al., 2007), indicating that the task is sensitive to impair-
ment. Finally, nonspecific THC-induced changes on CBF
may have confounded our results (Iannetti & Wise, 2007).
However, we have designed our study to minimize the
influence of this effect by comparing brain activity between
task-specific conditions and a closely matched control con-
dition, as the nonspecific effect of THC on blood flow can
be expected to be present in all conditions. Furthermore,
as we found both significant decreases and increases in
activity after THC administration, it is highly unlikely that
our findings can be explained by such nonspecific effects.
In conclusion, findings reported in this article contrib-
ute to the growing body of evidence that suggests the in-
volvement of the eCB system in learning and memory
processes. Our results further emphasize the eCB system
as a potential novel target for treatment of memory dis-
orders, encouraging further research into novel, eCB-
targeting compounds.
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